Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof
Journal
Oral Oncology
Journal Volume
51
Journal Issue
11
Pages
1004-1010
Date Issued
2015
Author(s)
Abstract
Summary Objective The treatment strategies for advanced oral squamous cell carcinoma (OSCC), especially with necrotic changes, are not effective. The programmed death ligand 1 (PD-L1) immune escape may be one of the underlying sources of resistance. Furthermore, anti-PD-L1 directed immunotherapy may be another choice for adjuvant therapy. Therefore, the expression of PD-L1 in advanced OSCC with necrotic changes is very important. Materials and methods A total of 218 eligible patients with advanced stage (stage III/IV) OSCC and neck metastasis were enrolled. The presence of necrosis was reviewed by pretreatment magnetic resonance imaging. Paired paraffin-embedded primary tumor and metastatic lymph nodes (LN) sections were stained with antibodies against hypoxia-inducible factor-1α (HIF-1α) and PD-L1. Moderate-to strong HIF-1α nuclear staining in >10% and cell surface PD-L1 expression in >5% of OSCC cells were recorded as a positive result. Results For advanced OSCC with necrotic changes, there was substantial agreement in primary tumor (kappa value 0.54) and almost perfect agreement in metastatic LN (kappa value 0.86) between HIF-1α and PD-L1 expression. The patients with both necrosis and positive PD-L1 expression in OSCC surrounding necrosis had worse disease control and survival outcomes. After multivariate analysis, metastatic LN necrosis and positive PD-L1 expression were found to be significant independent adverse factors. Conclusion Advanced OSCC patients with both necrosis and positive PD-L1 expression in OSCC surrounding necrosis had worse outcome. The aggressive behavior of advanced OSCC could be partially related to PD-L1 immune escape. These patients may be good candidates for anti-PD-L1 immunotherapy. ? 2015 Elsevier Ltd.
SDGs
Other Subjects
antibody; antineoplastic agent; hypoxia inducible factor 1alpha; programmed death 1 ligand 1; CD274 protein, human; hypoxia inducible factor 1alpha; programmed death 1 ligand 1; adjuvant chemoradiotherapy; adult; advanced cancer; aged; Article; cancer cell; cancer control; cancer prognosis; cancer recurrence; cancer staging; cancer survival; cell surface; controlled study; disease free survival; disease specific survival; distant metastasis; female; human; human tissue; immunohistochemistry; induction chemotherapy; lymph node metastasis; major clinical study; male; middle aged; mouth squamous cell carcinoma; neck metastasis; nuclear magnetic resonance imaging; overall survival; primary tumor; priority journal; protein expression; recurrence risk; treatment outcome; tumor necrosis; lymph node; metabolism; mouth tumor; neck; necrosis; pathology; prognosis; retrospective study; squamous cell carcinoma; very elderly; Adult; Aged; Aged, 80 and over; Antigens, CD274; Carcinoma, Squamous Cell; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Mouth Neoplasms; Neck; Necrosis; Prognosis; Retrospective Studies
Publisher
Elsevier Ltd
Type
journal article